RCS - hVIVO PLC - Positive data from novel human challenge models

hVIVOAnnouncement

Tue 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251111:nRSK9589Ga&default-theme=true

RNS Number : 9589G  hVIVO PLC  11 November 2025

hVIVO plc

("hVIVO", the "Company" or the "Group")

 

Positive data from multiple novel human challenge models

hVIVO presentations made at influential ESWI and World Vaccine Congress Europe
conferences

 

hVIVO plc (AIM: HVO), a full-service early phase Contract Research
Organisation (CRO) and the world leader in human challenge clinical trials,
announces key insights from its scientific presentations at the 10(th)
European Scientific Working Group on Influenza ("ESWI") Conference in
Valencia, and the World Vaccine Congress Europe in Amsterdam, which both took
place in October 2025.

 

hVIVO presented positive data from a number of newly developed human challenge
models, all demonstrating an acceptable safety and tolerability profile,
reinforcing hVIVO's continued world-leading capabilities in accelerating the
development of novel challenge agents and its readiness to meet customer
demand for innovative and effective clinical trial solutions.

 

Human Metapneumovirus ("hMPV") challenge model

hVIVO's Senior Study Physician, Dr Alexander Lima, presented the positive
findings from the newly developed, and world's only contemporary-strain hMPV
human challenge model. The presentation at ESWI, titled, "Disease
characteristics and immunological profiles obtained from newly developed hMPV
human challenge model", highlighted the model's strong performance using a
recent 2a strain, which compared favourably against hVIVO's established RSV A
model, a benchmark for model performance for this particular virus family. The
model demonstrated high infection and symptomatic disease attack rates and
robust AUC virology by qRT-PCR, and is now ready and available for vaccine and
antiviral human challenge trials.

 

SARS-CoV-2 Omicron challenge model

Alex Mann, Senior Director Clinical Science presented, "Development of a
SARS-CoV-2 Omicron BA5 human challenge model" at ESWI. This presentation
highlighted the success of hVIVO's Omicron human challenge model which
performs favourably in seropositive, previously vaccinated participants and
confirmed the model's suitability for use in vaccine and treatment studies. A
key insight from the presentation was the importance of timing of dosing
post-inoculation, particularly in the context of post-exposure prophylaxis.
This represents the first commercially available Omicron human challenge
model.

 

Respiratory Syncytial Virus B (RSV B) challenge model

At the World Vaccine Congress Europe, hVIVO's Chief Scientific Officer, Dr
Andrew Catchpole showcased the positive results from hVIVO's new RSV B model
titled, "High infection rates achieved with the worlds' first RSV B challenge
models key component of our RSV-hMPV-PIV combination vaccine efficacy testing
platform." The data confirmed the robustness of the RSV B model, which is now
available for vaccine and anti-viral efficacy testing. The development of the
RSV B and hMPV models, along with the Company's collecting of PIV
(parainfluenza virus) clinical samples, has enabled the Company to create a
comprehensive efficacy testing platform enabling the Company to test
individual components of the next generation combination vaccines under
development.

 

Any interested parties should contact bd@hvivo.com (mailto:bd@hvivo.com) to
learn more about these new models.

 

Dr Andrew Catchpole, Chief Scientific Officer of hVIVO, said: "We are
delighted to have presented such positive data across three pathogens, hMPV,
RSV B, and Omicron, at two of the industry's most influential scientific
conferences. These results not only validate our unmatched expertise in
designing and delivering new challenge models but also reinforce hVIVO's
commitment to accelerating the development of vital vaccines and therapeutics
and ensuring we have models that reflect industry's evolving needs."

For further information please contact:

 

 hVIVO plc                                       +44 (0)20 7756 1300
 Yamin 'Mo' Khan, Chief Executive Officer

 Stephen Pinkerton, Chief Financial Officer

 Cavendish Capital Markets Limited (Nominated Adviser                                                  +44 (0)20 7220 0500

and Joint Broker)
 Geoff Nash, Callum Davidson,

Trisyia Jamaludin, Harriet Ward

 Nigel Birks - Life Science Specialist Sales

 Louise Talbot - Sales

 Peel Hunt LLP (Joint Broker)                                               +44 (0)20 7418 8900
 James Steel, Dr Christopher Golden

 Davy (Joint Broker)                                                        +353 (0) 1 679 6363
 Anthony Farrell, Niall Gilchrist

 Walbrook PR (Financial PR & IR)                 +44 (0)20 7933 8780 or hvivo@walbrookpr.com (mailto:hvivo@walbrookpr.com)

 Paul McManus / Alice Woodings /                 +44 (0)7980 541 893 / +44 (0)7407 804 654/

+44 (0)7584 391 303
 Lianne Applegarth

 

 

Notes to Editors

hVIVO plc (https://hvivo.com/)  (Ticker: HVO) is full-service early phase
Contract Research Organisation (CRO) and the global leader in human challenge
trials. The company delivers end-to-end clinical development services to a
diverse and expanding client base, including seven of the world's ten largest
biopharma companies.

 

hVIVO specialises in conducting human challenge trials across multiple
infectious and respiratory indications, leveraging its state-of-the-art
quarantine facility in London-the largest of its kind worldwide. The Company
also offers comprehensive virology and immunology laboratory services under
the hLAB (https://hlabservices.com/)  brand.

 

Through its German subsidiary, CRS (https://crs-earlyphase.com/) , hVIVO
operates a 120-bed capacity across Mannheim and Kiel, providing early-phase
clinical trial services, including first-in-human and proof-of-concept
studies. Its second subsidiary, Venn Life Sciences
(https://www.vennlifesciences.com/) , offers Early Drug Development
Consulting and Biometry services to the biopharma sector.

 

The Group provides fully integrated drug development solutions from
preclinical stages through Phase II trials, alongside patient recruitment
via FluCamp (https://flucamp.com/) . Additionally, its five clinical sites
support outpatient Phase II and III trials, ensuring a seamless and
efficient pathway from discovery to late-stage development.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRADGBDBCGBDGUG



            Copyright 2019 Regulatory News Service, all rights reserved